Avanir Pharmaceuticals Inc (AVNR.OQ)

AVNR.OQ on NASDAQ Stock Exchange Global Select Market

16.99USD
18 Dec 2014
Price Change (% chg)

$0.07 (+0.41%)
Prev Close
$16.92
Open
$16.95
Day's High
$16.99
Day's Low
$16.93
Volume
819,984
Avg. Vol
1,364,766
52-wk High
$17.05
52-wk Low
$2.62

AVNR.OQ

Chart for AVNR.OQ

About

AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its... (more)

Overall

Beta: 0.88
Market Cap (Mil.): $3,278.40
Shares Outstanding (Mil.): 193.76
Dividend: --
Yield (%): --

Financials

  AVNR.OQ Industry Sector
P/E (TTM): -- 176.21 37.24
EPS (TTM): -0.31 -- --
ROI: -31.90 -0.64 18.21
ROE: -34.56 -1.77 19.11
Search Stocks

US STOCKS-Energy shares lead Wall St higher; telecoms slip

* More cars and trucks sold in November than analysts expected

02 Dec 2014

US STOCKS-Energy shares lead Wall St higher in broad advance

* More cars and trucks sold in November than analysts expected

02 Dec 2014

Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff

- Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.

02 Dec 2014

UPDATE 3-Japan's Otsuka to buy Avanir for $3.5 bln ahead of patent cliff

Dec 2 - Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.

02 Dec 2014

US STOCKS-Wall St rises, boosted by energy despite oil weakness

* Indexes up: Dow 0.4 pct, S&P 0.5 pct, Nasdaq 0.4 pct (Updates to midday trading)

02 Dec 2014

US STOCKS-Wall St rises, but oil continues to weigh

* Dow, S&P 500 both up 0.2 pct, Nasdaq up 0.3 pct (Updates to open)

02 Dec 2014

Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff

By Reuters Staff - Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.

02 Dec 2014

US STOCKS-Futures point to higher open, crude oil falls again

* Futures up: Dow 36 pts, S&P 3.25 pts, Nasdaq 8 pts (Updates prices)

02 Dec 2014

US STOCKS-Futures slightly higher after decline, oil down again

* Futures up: Dow 53 pts, S&P 5.25 pts, Nasdaq 12 pts (Updates prices)

02 Dec 2014

US STOCKS-Futures slightly higher after decline, oil down again

NEW YORK, Dec 2 - U.S. stock index futures were slightly higher on Tuesday, indicating a slight rebound from the previous session's broad decline, which was the S&P 500's weakest day in a month.

02 Dec 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $106.81 +2.74
Novartis AG (NOVN.VX) CHF92.10 +3.15
Pfizer Inc. (PFE.N) $31.97 +0.85
Merck & Co., Inc. (MRK.N) $58.98 +1.35
Bayer AG (BAYGn.DE) €115.00 +2.90
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: Jefferson Research
$20.00
Provider: S&P Capital IQ Quantitative Report
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks